Pyxis Oncology (PYXS) Preferred Stock Liabilities (2020 - 2021)
Pyxis Oncology's (PYXS) quarterly Preferred Stock Liabilities came in at $172.1 million in Q3 2021, up 684.25% year-on-year from $21.9 million in Q3 2020, and little changed on a QoQ basis from $172.1 million in Q2 2021.
Pyxis Oncology (PYXS) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of Preferred Stock Liabilities data on file, last reported at $172.1 million in Q3 2021.
- On a quarterly basis, Preferred Stock Liabilities rose 684.25% year-over-year to $172.1 million in Q3 2021; TTM through Sep 2021 was $172.1 million, a 684.25% increase from a year earlier, with the FY2020 full-year figure at $21.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2021 stood at $172.1 million, roughly flat from $172.1 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for PYXS reached as high as $172.1 million in Q2 2021 and fell as low as $21.9 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 172.08 Mn |
| Jun 30, 2021 | 172.08 Mn |
| Mar 31, 2021 | 21.94 Mn |
| Dec 31, 2020 | 21.94 Mn |
| Sep 30, 2020 | 21.94 Mn |